Photo from wikipedia
Rivaroxaban has the most available data to support the use of prothrombin complex concentrates (PCC) as a reversal agent. However, PCC might increase the incidence of thrombotic events by shifting… Click to show full abstract
Rivaroxaban has the most available data to support the use of prothrombin complex concentrates (PCC) as a reversal agent. However, PCC might increase the incidence of thrombotic events by shifting the haemostatic balance towards hypercoagulability. We assessed the in vitro efficacy and safety of three 4-factor PCCs for reversing rivaroxaban anticoagulant effect. Our in vitro finding indicates that 4-factor PCCs at the dose of 25 U.kg − 1 may be sufficient to reverse rivaroxaban anticoagulant effect.
Keywords:
prothrombin complex;
anticoagulant effect;
complex concentrates;
rivaroxaban anticoagulant
Journal Title: Thrombosis Journal
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Thrombosis Journal
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!